20/20 Biolabs Common Stock Total Revenue

The latest total revenue for AIDX is $2M as of June 2026. That is below the sector sector average of $1.3B. Investors often review this figure alongside 20/20 Biolabs Common Stock's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, AIDX currently prints $2M for total revenue, while the sector average sits near $1.3B. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at 20/20 Biolabs Common Stock's growth, margins, and balance sheet.

A total revenue figure of $2M for AIDX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.3B. Explore the charts below for those layers of context.

After noting AIDX's total revenue ($2M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.